Erlotinib
About
Therapy type: Targeted therapy
Therapy strategy: EGFR inhibition
Mappings
NCI Thesaurus: Erlotinib (coding:ncit:C65530)
RxNorm: erlotinib (coding:rxcui:337525, coding:omop:1325363)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Erlotinib | |
| FDA (2) | EGFR p.L858R | Non-Small Cell Lung Cancer | Erlotinib | |
| FDA (2) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| FDA (2) | EGFR p.L858R | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| EMA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Bevacizumab, Erlotinib | |
| EMA (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Bevacizumab, Erlotinib | |
| EMA (1) | EGFR activating variants | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| EMA (2) | EGFR activating variants | Non-Small Cell Lung Cancer | Erlotinib |